Omalizumab biosimilar (Synermore Biologics)

奥马佐单抗生物类似药 (Synermore Biologics)

Report date: 2025/10/20 14:43:22

Base Information

Drug NameOmalizumab biosimilar (Synermore Biologics)
Drug Alias NameXolair biosimilar奥玛利珠单抗生物仿制药 (Synermore Biologics)奥马佐单抗生物仿制药 (Synermore Biologics)奥马珠单抗生物仿制药 (Synermore Biologics)Kelingda +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsAllergic asthmaChronic Urticaria
Global Approved IndicationsChronic Urticaria
Approved Indications in ChinaChronic Urticaria
Original Approved Country/TerritoryMainland China
Original Approved Date2024/09/26
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSynermore Biologics (Suzhou) Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesJushi Biopharmaceutical Co Ltd
Inactive CompaniesCspc Baike (Shandong) Biopharmaceutical Co Ltd
Active IndicationsAllergic asthmaChronic Urticaria
Inactive IndicationsN/A

Other Information

ATC CodeR03DX05
Related LinksN/A